Christine Banman, RD, LDN

Christine Banman, RD, LDN

Education:

  • 9/96 - 6/97 University of Alabama at Birmingham, Birmingham, AL
    Dietetic Internship and Graduate School – School of Nutrition Sciences
  • 3/93 – 12/95 University of Montevallo, Montevallo, AL
    Bachelor of Science, Food and Nutrition Sciences
    Magna Cum Laude, Kappa Omicron Nu Honor Society

Employment History:

  • 3/2005 – present Mountain Kidney & Hypertension Associates, Asheville, NC
    Renal Dietitian, Chronic Kidney Disease Educator, Study Coordinator

Provide Medical Nutrition Therapy and CKD education to stages 1-5 CKD patients. Coordinate chronic kidney disease educational classes for patients with stage 1-5 CKD. Assist in the patient screening, recruitment and study visit monitoring for clinical research projects.

  • 10/97 – 3/2005 DaVita Asheville Kidney Center, Asheville, NC
  • Renal Dietitian, Study Coordinator
  • DaVita Sylva Dialysis Center, Sylva, NC
  • DaVita Weaverville Dialysis Center, Weaverville, NC
  • DaVita Dialysis Care of Rutherford County, Forest City, NC

Provided renal diet guidance to patients on chronic hemodialysis and peritoneal dialysis. Participated in monthly care planning with multidisciplinary team; manage vitamin D, Sensipar, and binder dosing for all patients. Assisted as study coordinator in the recruitment and enrollment, and study monitoring for clinical research projects.

  • 8/97 - 12/98 Park Ridge Hospital, Fletcher, NC
  • Part-time Clinical Dietitian

Provided nutritional care and education to patients in medical surgery unit, geriatric psych unit and adolescent care unit. Assisted clients in the HOPE eating disorders program with meal planning, menus, and nutrition education.

Clinial Research:

Amgen Multicenter Clinical Trial; P.I. - Brian N. Ling, M.D.; Co-P.I. - Brian K. England, M.D.;
AMG 073 990101: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD); 07/99 to 02/01.

Shire Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D. .; Co-P.I. – Joseph R. Aiello, M.D.;
LAM IV-307: An Open label, Randomized, Multicenter, Phase III, Comparator Controlled Parallel Group Study to Assess the Long-Term Safety and Efficacy of Lanthanum Carbonate in Chronic Renal Failure Patients Receiving Hemodialysis; 02/00 to 11/02

Amgen Multicenter Clinical Registry; P.I.: Brian N. Ling; STRIDE Chronic Renal Insufficiency
Registry; 10/00 to 10/03

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
AMG 073 20000237 A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Renal Failure; 02/01-11/01

Amgen Multicenter Clinical Trial; P.I. - Brian N. Ling, M.D.; Co-P.I. - John A. Manley, M.D.;
AMG 073 20000130A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD); 06/01 to 10/05

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
AMG 073 20000172 A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis; 11/01 to 4/03

GelTex Pharmaceuticals Multicenter Clinical Trial; P.I. – Brian N. Ling; Co-P.I. – John A. Manley;
GTC-68-401: A Randomized, Open Label, Parallel Design Study of Renagel® Phosphate Binder Versus Calcium-Based Phosphate Binders In Hemodialysis Patients; 01/02 to 03/05

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
Darbepoetin alfa 20010212 A Study of Darbepoetin alfa Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects with Anemia; 02/02 to 09/03

Amgen Multicenter Clinical Trial; P.I. - Brian N. Ling, M.D.; Co-P.I. - John A. Manley, M.D.;
AMG 073 20010240 A Placebo-controlled, Double-blind, Extension Study to Assess the Long term Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End-Stage Renal Disease; 07/02 to 09/03

Luitpold Multicenter Clinical Trial: P.I. – Brian N. Ling, M.D.; Co-P.I. – Katherine R. Freyfogle, M.D.
1VEN02022, A Study of the Efficacy and Safety of Venofer® [Iron Sucrose Injection] in Anemic Patients Receiving Peritoneal Dialysis; 10/02 to 02/04

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
AMG 073 20020158: A Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens are Used in Subjects with Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD); 01/03 to 10/05

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
AMG 073 20020390: TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on CinacalceT; 08/03 to 09/04

Luitpold Multicenter Clinical Trial: P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
1VEN03027, Comparison of the Safety and Efficacy of Intravenous Iron versus Oral Iron in Chronic Renal Failure Subjects with Anemia; 10/03 to 06/04

Nabi Multicenter Clinical Trial: P.I. - Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
Nabi 1371: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX®, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis; 01/04 to present

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
Darbepoetin alfa 20030153: A Multicenter, Single Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease Not Receiving Dialysis; 03/04 to 10/05

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
Darbepoetin alfa 20030237: A Multi-Center, Single-Arm Study Evaluating De Novo Once Every Two Week Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease Not Receiving Dialysis; 04/04 to 05/05

Shire Multicenter Clinical Trial; P.I. - Brian N. Ling, M.D.; Co-P.I. – John A. Manley, M.D.;
A Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-in and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis; 07/04 to 01/06

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
Darbepoetin alfa 20010184: TREAT – Trial to Reduce Cardiovascular Events with Aranesp Therapy; 10/04 to present

Amgen Multicenter Clinical Registry: P.I. – Brian N. Ling, M.D.;
20040159: A Multi-center, Observational Registry of Subjects with Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD); 02/05 to present

Amgen Multicenter Clinical Trial; P.I. – Brian N. Ling, M.D.; Co-P.I. – Joseph R. Aiello, M.D.;
Darbepoetin alfa 20040180: An Open Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease; 03/05 to 10/06

Affymax Multicenter Clinical Trial; P.I. – Joseph Aiello, MD., Co-P.I. – John Manley, MD.;
AFX01-13: A Phase 3, Randomized, Active-Controlled, Open-label Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure (CRF) not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment; 1/07 to present

Shire Multicenter Clinical Registry: P.I. – Joseph R. Aiello, M.D.;
SELECT SPD405-404: A Phase-IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with Lanthanum Carbonate (Fosrenol); 3/08 to present

Luitpold Multicenter Clinical Trial: P.I. – Joseph Aiello, M.D.;
1VIT07018: A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients; 4/08 to present

Affymax Multicenter Clinical Trial; P.I. – Joseph R. Aiello, M.D.; Co-P.I. – William Durham, MD; Co-P.I. Samuel Bryson Fleming, MD;
AFX01-14: A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin; 9/08 to present.

Kremezin Multicenter Clinical Trial; P.I. – Joseph R. Aiello, M.D.;
KRM-306: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease; 8/08 to present.